In Houston, TX we are developing a Nanomedicine Scientific Advisory Board. Houston has key organizations driving nanomedicine and cancer research. Our executive committee has developed a framework to address the issues of translation from academia, thru the FDA and into commercial space. This 5-year study, beginning Jan 2016 will review the gaps and barriers in the global nanomedicine market. I would like to learn more about NCL’s translation for Nanomedicine initiative.

Agenda:

– Nanotechnology Characterization Laboratory History and Origins

– Houston EMBS Nanomedicine Translation 5-year Case Study Iniaitive

– Guidence from NCL Leadership in Reference to this Iniaitive 

– Possibility in Partnering with NCL and it’s Leadership on the SAB Activities 

Location:
Bldg: Virtual
Houston , Texas